Sara A. Hurvitz, MD, on the DESTINY-Breast03 Trial: T-DXd Versus T-DM1 for HER2+ Breast Cancer

Posted: Tuesday, March 15, 2022

Sara A. Hurvitz, MD, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, interprets the clinical implications of phase III findings from the DESTINY-Breast03 trial, which favored the use of ado-trastuzumab deruxtecan (T-DXd) over standard-of-care trastuzumab emtansine (T-DM1) for patients with HER2-positive metastatic breast cancer. In addition to the efficacy data, Dr. Hurvitz examines safety differences between the regimens.